Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Heard, Bryan J ^a,b   Martin, Liam ^a,b   Rattner, Jerome B ^a,b   Frank, Cyril B ^a,b   Hart, David A ^a,b   Krawetz, Roman ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KNEE; MALE; OSTEOARTHRITIS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN EXPRESSION; SYNOVIAL FLUID; SYNOVIAL FLUID LEVEL;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS, KNEE; PREDICTIVE VALUE OF TESTS; PRINCIPAL COMPONENT ANALYSIS; SYNOVIAL FLUID; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84871790038     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-126     Document Type: Article

References (44)

1. - 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G, Arthritis Rheum 2010 62 2569 81 10.1002/art.27584 20872595
2. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Arthritis Rheum 1986 29 1039 49 10.1002/art.1780290816 3741515
3. Review: Collagen markers in early arthritic diseases. Elsaid KA, Chichester CO, Clin Chim Acta 2006 365 68 77 10.1016/j.cca.2005.09.020 16257399
4. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Deberg M, Dubuc JE, Labasse A, Sanchez C, Quettier E, Bosseloir A, Crielaard JM, Henrotin Y, Ann Rheum Dis 2008 67 168 74 10.1136/ard.2007.073452 17644542
5. Biomarkers of incident radiographic knee osteoarthritis: do they vary by chronic knee symptoms? Golightly YM, Marshall SW, Kraus VB, Renner JB, Villaveces A, Casteel C, Jordan JM, Arthritis Rheum 2011 63 2276 83 10.1002/art.30412 21506100
6. Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study. Chen HC, Shah S, Stabler TV, Li YJ, Kraus VB, Osteoarthritis Cartilage 2008 16 1054 9 10.1016/j.joca.2007.12.010 18291686
7. Fragmentation of proteins in cartilage treated with interleukin-1: specific cleavage of type IX collagen by matrix metalloproteinase 13 releases the NC4 domain. Danfelter M, Onnerfjord P, Heinegard D, J Biol Chem 2007 282 36933 41 10.1074/jbc.M702491200 17951262
8. The role of cytokines in osteoarthritis pathophysiology. Fernandes JC, Martel-Pelletier J, Pelletier JP, Biorheology 2002 39 237 46 12082286
9. Matrix metalloproteinases: role in arthritis. Burrage PS, Mix KS, Brinckerhoff CE, Front Biosci 2006 11 529 43 10.2741/1817 16146751
10. Joint diseases and matrix metalloproteinases: a role for MMP-13. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J, Curr Pharm Biotechnol 2008 9 47 54 10.2174/138920108783497659 18289056
11. Variation of cell and matrix morphologies in articular cartilage among locations in the adult human knee. Quinn TM, Hunziker EB, Hauselmann HJ, Osteoarthritis Cartilage 2005 13 672 8 10.1016/j.joca.2005.04.011 15970445
12. Differential modulation of degradative and repair responses of interleukin-1-treated chondrocytes by platelet-derived growth factor. Harvey AK, Stack ST, Chandrasekhar S, Biochem J 1993 292 Pt 1 129 36 8503839
13. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Cawston TE, Wilson AJ, Best Pract Res Clin Rheumatol 2006 20 983 1002 10.1016/j.berh.2006.06.007 16980219
14. The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis. Smith GN, Front Biosci 2006 11 3081 95 10.2741/2034 16720377
15. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y, Ann Rheum Dis 2000 59 455 61 10.1136/ard.59.6.455 10834863
16. Metalloproteinase-7 contributes to joint destruction in Staphylococcus aureus induced arthritis. Gjertsson I, Innocenti M, Matrisian LM, Tarkowski A, Microb Pathog 2005 38 97 105 10.1016/j.micpath.2004.12.005 15748811
17. Association of increased expression of macrophage elastase (matrix metalloproteinase 12) with rheumatoid arthritis. Liu M, Sun H, Wang X, Koike T, Mishima H, Ikeda K, Watanabe T, Ochiai N, Fan J, Arthritis Rheum 2004 50 3112 7 10.1002/art.20567 15476203
18. Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. Howard EW, Bullen EC, Banda MJ, J Biol Chem 1991 266 13070 5 1649175
19. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin. Baragi VM, Fliszar CJ, Conroy MC, Ye QZ, Shipley JM, Welgus HG, J Biol Chem 1994 269 12692 7 8175679
20. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. O'Connell JP, Willenbrock F, Docherty AJ, Eaton D, Murphy G, J Biol Chem 1994 269 14967 73 8195131
21. Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Nguyen Q, Willenbrock F, Cockett MI, O'Shea M, Docherty AJ, Murphy G, Biochemistry 1994 33 2089 95 10.1021/bi00174a015 8117665
22. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. Stetler-Stevenson WG, Krutzsch HC, Liotta LA, J Biol Chem 1989 264 17374 8 2793861
23. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, Seiki M, J Biol Chem 1998 273 16098 103 10.1074/jbc.273.26.16098 9632662
24. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. Butler GS, Apte SS, Willenbrock F, Murphy G, J Biol Chem 1999 274 10846 51 10.1074/jbc.274.16.10846 10196161
25. Characterization of C-terminally truncated human tissue inhibitor of metalloproteinases-4 expressed in Pichia pastoris. Stratmann B, Farr M, Tschesche H, Biol Chem 2001 382 987 91 11501766
26. An evaluation of commercial fluorescent bead-based luminex cytokine assays. Djoba Siawaya JF, Roberts T, Babb C, Black G, Golakai HJ, Stanley K, Bapela NB, Hoal E, Parida S, van Helden P, Walzl G, PLoS One 2008 3 2535 10.1371/journal.pone.0002535 18596971
27. Quantitative validation and comparison of multiplex cytokine kits. Richens JL, Urbanowicz RA, Metcalf R, Corne J, O'Shea P, Fairclough L, J Biomol Screen 2010 15 562 8 10.1177/1087057110362099 20176857
28. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Elshal MF, McCoy JP, Methods 2006 38 317 23 10.1016/j.ymeth.2005.11.010 16481199
29. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. Valentin MA, Ma S, Zhao A, Legay F, Avrameas A, J Pharm Biomed Anal 2011 55 869 77 10.1016/j.jpba.2011.03.033 21530130
30. Correlation of XMAP and ELISA cytokine profiles; development and validation for immunotoxicological studies in vitro. Codorean E, Nichita C, Albulescu L, Raducan E, Popescu ID, Lonita AC, Albulescu R, Roum Arch Microbiol Immunol 2010 69 13 9 21053779
31. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ, Yang HI, Yoo MC, Rheumatol Int 2011 31 543 7 10.1007/s00296-010-1592-1 20665024
32. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T, J Rheumatol 2001 28 22 8 11196534
33. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Maeda S, Sawai T, Uzuki M, Takahashi Y, Omoto H, Seki M, Sakurai M, Ann Rheum Dis 1995 54 970 5 10.1136/ard.54.12.970 8546529
34. Relationship between Investigative Biomarkers and Radiographic Grading in Patients with Knee Osteoarthritis. Anitua E, Sanchez M, de la Fuente M, Azofra J, Zalduendo M, Aguirre JJ, Andia I, Int J Rheumatol 2009 2009 747432 20130801
35. The potential of multiple synovial-fluid protein-concentration analyses in the assessment of knee osteoarthritis. Driban JB, Balasubramanian E, Amin M, Sitler MR, Ziskin MC, Barbe MF, J Sport Rehabil 2010 19 411 21 21116010
36. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Tchetverikov I, Lohmander LS, Verzijl N, Huizinga TW, TeKoppele JM, Hanemaaijer R, DeGroot J, Ann Rheum Dis 2005 64 694 8 10.1136/ard.2004.022434 15834054
37. Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Catterall JB, Stabler TV, Flannery CR, Kraus VB, Arthritis Res Ther 2010 12 229 10.1186/ar3216 21194441
38. Matrix metalloproteinase expression in the spondyloarthropathies. Zhu J, Yu DT, Curr Opin Rheumatol 2006 18 364 8 10.1097/01.bor.0000231904.04548.09 16763456
39. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Mahmoud RK, El-Ansary AK, El-Eishi HH, Kamal HM, El-Saeed NH, Ital J Biochem 2005 54 248 57 16688934
40. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Farahat MN, Yanni G, Poston R, Panayi GS, Ann Rheum Dis 1993 52 870 5 10.1136/ard.52.12.870 8311538
41. Cytokine production in culture by cells isolated from the synovial membrane. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M, J Autoimmun 1989 2 Suppl 177 86 2505790
42. Five types of inflammatory arthritis following total knee arthroplasty. Niki Y, Matsumoto H, Otani T, Tomatsu T, Toyama Y, J Biomed Mater Res A 2007 81 1005 10 17265437
43. Phagocytic function of polymorphonuclear leukocytes in rheumatic diseases. Turner RA, Schumacher R, Myers AR, J Clin Invest 1973 52 1632 5 10.1172/JCI107342 4578156
44. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Jones EA, English A, Henshaw K, Kinsey SE, Markham AF, Emery P, McGonagle D, Arthritis Rheum 2004 50 817 827 10.1002/art.20203 15022324